MedTrace Logo

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

NCT06393816 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-08-02

No results posted yet for this study

Summary

The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review

Conditions

  • Large Cell Neuroendocrine Carcinoma of the Lung

Interventions

DRUG

Durvalumab with etoposide and Carboplatin/Cisplatin

Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas of the Lung. All patients (either with confirmed diagnosis or not) will be treated and followed-up: * During the induction: every 3 weeks for 12 weeks (4 cycles) * During the maintenance: every 4 weeks for 24 months

Sponsors & Collaborators

  • Groupe Francais De Pneumo-Cancerologie

    collaborator OTHER

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Luc ODIER, MD · Hôpital Nord-Ouest, Villefranche sur Saône

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2028-09-30
Completion
2029-09-30

Countries

  • France
  • Reunion

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06393816 on ClinicalTrials.gov